Filing Analysis
Profound Medical Corp. reported the results of its Annual General and Special Meeting held on May 13, 2026. Shareholders elected eight directors, reappointed PricewaterhouseCoopers LLP as auditors, and approved unallocated units under the company's long-term incentive plan.
🚩 Red Flags
- Significant shareholder opposition to the Long-Term Incentive Plan, with 36.078% voting against the resolution.
- Notable 'Withheld' votes for certain directors, specifically Arthur Rosenthal (21.001% withheld) and Brian Ellacott (18.446% withheld).
📋 Key Facts
- The meeting was held on May 13, 2026, with results filed on May 15, 2026.
- Eight director nominees were elected, including CEO Arun Menawat (90.257% for).
- PricewaterhouseCoopers LLP was reappointed as the auditor with 99.497% support.
- The resolution to approve unallocated restricted share units (RSUs) and deferred share units (DSUs) passed with 63.922% of the vote.
Profound Medical Corp. announced that its TULSA Procedure™ will be featured in four oral presentations at the American Urological Association’s (AUA) Annual Meeting on May 16, 2026.
📋 Key Facts
- The TULSA Procedure™ will be highlighted in four oral presentations.
- The presentations will take place at the AUA Annual Meeting in Washington, DC.
- The event is scheduled for May 16, 2026.
- The information was furnished under Item 7.01 (Regulation FD Disclosure).
Profound Medical Corp. announced its financial results for the first quarter ended March 31, 2026, and provided a business update. The information was furnished via a press release as part of a routine quarterly reporting cycle.
📋 Key Facts
- Financial results cover the quarter ended March 31, 2026.
- The report was filed on May 7, 2026, under Item 2.02 Results of Operations and Financial Condition.
- A press release (Exhibit 99.1) was furnished alongside the filing.
- The filing includes a signature from Rashed Dewan, Chief Financial Officer.
Profound Medical Corp. announced it will release its first quarter 2026 financial results after market close on May 7, 2026. The company will host a conference call and webcast at 4:30 p.m. ET that same day to discuss the results and business developments.
📋 Key Facts
- Earnings release date for Q1 2026 is set for May 7, 2026.
- Conference call scheduled for May 7, 2026, at 4:30 p.m. Eastern Time.
- The announcement was made via a press release furnished as Exhibit 99.1.
- The filing is made under Item 7.01 (Regulation FD Disclosure).
Profound Medical Corp. announced it will present a business update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 22, 2026.
📋 Key Facts
- The presentation is scheduled for April 22, 2026, at 10:00 a.m. Eastern Time.
- The event will take place at the Metro Toronto Convention Centre and will be available via live broadcast.
- The announcement was formally disclosed under Item 7.01 (Regulation FD Disclosure).
Profound Medical Corp. announced that its TULSA Procedure™ will be featured in several presentations at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The event is scheduled to take place in Toronto, ON, from April 11-15, 2026.
📋 Key Facts
- The Company's interventional MRI TULSA Procedure™ will be highlighted at the 2026 SIR Annual Scientific Meeting.
- The meeting is scheduled for April 11-15, 2026, in Toronto, Ontario.
- The disclosure was made under Item 7.01 (Regulation FD Disclosure) and includes a press release as Exhibit 99.1.
- The information in the filing is furnished and not deemed 'filed' for regulatory liability purposes.
Profound Medical Corp. announced that Texas Prostate, led by Dr. James Cochran, has completed its 100th TULSA Procedure™ at Dallas Medical Center. The announcement highlights the continued clinical adoption and utilization of the company's TULSA technology in a real-world medical setting.
📋 Key Facts
- Texas Prostate achieved its 100th TULSA Procedure™ milestone.
- The procedures were performed at Dallas Medical Center’s state-of-the-art MRI suite.
- The announcement was made via a press release dated March 27, 2026.
- The lead physician for these procedures is Dr. James Cochran.
Profound Medical Corp. announced that its CAPTAIN trial, comparing the MRI-guided TULSA Procedure™ to robotic radical prostatectomy, has successfully met its primary safety endpoint.
📋 Key Facts
- The CAPTAIN trial is a head-to-head study comparing TULSA Procedure™ against robotic radical prostatectomy.
- The primary safety endpoint of the trial was successfully met as of March 13, 2026.
- The announcement was made via a press release furnished under Item 7.01 (Regulation FD).
- The TULSA Procedure is the company's core MRI-guided therapeutic technology.
Profound Medical Corp. announced the resignation of director Kris Shah and the immediate appointment of Frank Baylis to the Board of Directors effective March 5, 2026. The transition appears to be a routine board refresh as there were no reported disagreements.
📋 Key Facts
- Kris Shah resigned from the Board of Directors effective March 5, 2026.
- Frank Baylis was appointed to fill the vacancy effective immediately.
- The resignation was not the result of any disagreement with the Company.
- Mr. Baylis will receive an annual retainer of $50,000 and is eligible for annual equity awards.
- Mr. Baylis will serve until the 2026 annual meeting of stockholders.
Profound Medical Corp. announced an upcoming investor conference call scheduled for March 13, 2026, to discuss clinical outcomes from its CAPTAIN trial. The announcement was furnished via a press release under Regulation FD disclosure requirements.
📋 Key Facts
- Conference call scheduled for March 13, 2026, at 11:30 a.m. ET
- The call will specifically address clinical outcomes of the Company's CAPTAIN trial
- The filing was made under Item 7.01 (Regulation FD Disclosure)
- Rashed Dewan, CFO, signed the report on March 9, 2026
Profound Medical Corp. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The filing serves as a formal vehicle to furnish the earnings press release and provide a business update.
📋 Key Facts
- Announced Q4 and FY 2025 financial results on March 5, 2026.
- Information furnished under Item 2.02 (Results of Operations and Financial Condition).
- Includes Exhibit 99.1, the press release detailing performance.
- Signed by CFO Rashed Dewan.